Supernus Pharmaceuticals Inc
$ 49.94
-0.34%
15 Apr - close price
- Market Cap 2,875,631,000 USD
- Current Price $ 49.94
- High / Low $ 50.91 / 49.48
- Stock P/E N/A
- Book Value 18.48
- EPS -0.68
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.04 %
- 52 Week High 59.68
- 52 Week Low 29.16
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$63.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.8821 | -0.8 | 0.4 | 0.4363 | 0.5483 | 0.69 | 0.36 | 0.26 | 0.89 | 0.24 | -0.02 | 0.29 |
| Estimated EPS | 0.41 | 0.14 | 0.48 | 0.38 | 0.52 | 0.44 | 0.31 | 0.38 | 0.55 | 0.08 | -0.23 | 0.17 |
| Surprise | 0.4721 | -0.94 | -0.08 | 0.0563 | 0.0283 | 0.25 | 0.05 | -0.12 | 0.34 | 0.16 | 0.21 | 0.12 |
| Surprise Percentage | 115.1463% | -671.4286% | -16.6667% | 14.8158% | 5.4423% | 56.8182% | 16.129% | -31.5789% | 61.8182% | 200% | 91.3043% | 70.5882% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SUPN
2026-04-13 08:54:00
Tudor Investment Corp ET AL has invested $1.43 million in Supernus Pharmaceuticals, purchasing 30,015 shares. This investment by the hedge fund signals confidence in the specialty pharmaceutical company's growth potential and its focus on developing CNS therapies. The transaction was disclosed on April 13, 2026, and highlights continued institutional interest in Supernus Pharmaceuticals' product pipeline and financial outlook.
2026-04-12 19:56:00
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) shows strong sentiment across all horizons, leading to an overweight bias according to AI models. The analysis highlights a mid-channel oscillation pattern with an exceptional 40.0:1 risk-reward setup, targeting an 11.3% gain with a minimal 0.3% risk. Three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis indicating strong signals across near-term, mid-term, and long-term horizons.
2026-04-10 08:10:29
Supernus Pharmaceuticals (SUPN) has shown strong 1-year returns of 62.5% despite recent mixed short-term performance. The company is considered 18.3% undervalued with a narrative fair value of approximately $63.17, driven by deep pipeline progress in late-stage candidates like SPN-820 and SPN-443. However, risks include heavy reliance on key existing products and execution challenges with new offerings.
2026-04-09 08:39:46
Supernus Pharmaceuticals (SUPN) has shown strong 1-year returns of 62.5% despite recent mixed short-term performance. The stock is considered 18.3% undervalued, with a narrative fair value of approximately $63.17, driven by deep pipeline progress in late-stage candidates like SPN-820 and SPN-443. Investors are advised to examine underlying data and consider potential risks such as reliance on key products.
2026-04-07 22:09:50
Supernus Pharmaceuticals has agreed to acquire the asset portfolio for the candidate drug NV-5138 (SPN-820), as disclosed in a recent SEC filing. This acquisition includes both the core intellectual property rights and existing inventory of the drug. The move is a strategic step for Supernus to expand its product pipeline.
2026-04-07 21:09:50
Supernus Pharmaceuticals, Inc. has acquired all rights to the compound NV-5138 (SPN-820) from Navitor Pharmaceuticals, Inc., through an asset purchase agreement. The acquisition involves Supernus completing one Phase 2b study and potentially paying up to $350 million in milestone payments based on development, regulatory, and commercial achievements. A key clause allows Supernus to cease further obligations if the Phase 2b study is unsuccessful, limiting its downside risk.
